Japan· JP-1139016S1020
フェンフルラミン塩酸塩
A fenfluramine product containing フェンフルラミン塩酸塩, registered in Japan by 日本新薬, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Fenfluramine is registered in 2 of 19 countries.
Countries holding a registration under ATC A08AA02 (fenfluramine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Fenfluramine · ATC A08AA02
2 / 19 countries
- Finlandprice
- Japan
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- フェンフルラミン塩酸塩
- Manufacturer
- 日本新薬
- Country
- Japan (JP)
- ATC code
- A08AA02
- ATC class
- Fenfluramine
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
349 interactions on record for fenfluramine.
Graded by severity as the source publishes them — 85 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fenfluramine · interactions on record
349 records
- 85 severe
- 260 moderate
- 4 minor
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fenfluramine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFINTEPLAUCB Pharma SA, Brusel
- NorwayFinteplaUCB Pharma S.A.
- ItalyFINTEPLA*os soluz 120 ml 2,2 mg/ml + 1 adattatore per flacone + 2 sir 3 ml + 2 sir 6 mlUCB PHARMA S.A.
- SwitzerlandFintepla 2.2 mg/ml, solution buvableUCB-Pharma SA
- United KingdomFintepla 2.2mg/ml oral solutionUCB Pharma Ltd
- IrelandFintepla 2.2 mg/ml oral solutionUCB Pharma S.A.
- IcelandFinteplaUCB Pharma S.A.*
- NetherlandsFintepla 2,2 mg/ml drankUCB Pharma S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Fintepla
- Liechtenstein · Fintepla
- Norway · Fintepla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/142534df-f7d2-4727-9fbd-e394cb946cb6 GET /v1/drugs/142534df-f7d2-4727-9fbd-e394cb946cb6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．２２％１ｍＬ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1139016S1020",
"category": "内用薬",
"price_yen": 1618.7,
"generic_name": "フェンフルラミン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1139",
"transitional_expiry": null
}See everything about fenfluramine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.